Abstract
A phase II randomized clinical trial was conducted by Taiwan Cooperative Oncology Group (TCOG) to compare the efficacy and safety between the triplet regimen of S-1, leucovorin, oxaliplatin and gemcitabine (SLOG) with the modified FOLFIRNOX (mFOLFIRNOX) as the first-line treatment in locally advanced or metastatic pancreatic ductal Adenocarcinoma (PDAC) patients (TCOG T5217, ClinicalTrials.gov NCT 03443492). The purpose of this study is to assess the cost-effectiveness of SLOG versus mFOLFIRNOX for the group of Metastatic PDAC patients based on the study results from TCOG T5217.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
